The Impact of the COVID-19 Pandemic on Testicular Cancer

Sponsor
Ankara Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05083143
Collaborator
(none)
50
1
8.8
5.7

Study Details

Study Description

Brief Summary

In this study, investigators aim to reveal how the COVID-19 pandemic process affects testicular cancer presentations, tumor stages, the time elapsed between diagnosis and intervention, tumor recurrence and progression, which are oncological outcomes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: COVID-19 pandemic

Detailed Description

The rapid spread of the 2019 coronavirus disease (COVID-19) caused by a novel betacoronavirus known as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has had dramatic effects on individuals and health systems around the world. Beyond those infected with SARS-CoV-2,the intense demand for limited health system resources has led to reduced capacity, rapid depletion of healthcare systems and hospitals becoming a source of virus transmission.

Urology associations and reference centers have issued recommendations to inform urology care during the COVID-19 outbreak. It is essential that urologists give priority to patient safety. Potential delays in the diagnosis and treatment of urological conditions and the additional burden on healthcare resources must be balanced against the risks of exposure to COVID-19. While this situation aims to conserve healthcare resources, it has created the risk of delaying cancer treatment. As a result, the transformation of health services and the increasing interest of the public in avoiding exposure to the disease has led to a decrease in the number of hospital admissions.

The effects of the pandemic on patients with testicular cancer due to a decrease in emergency room and urology clinic admissions are not clear. During theCOVID-19 outbreak, the EAU (European Association of Urology) panel of testicular cancer published an evidence-based guideline. According to this guideline, four priority groups were formed and a certain period of delaying treatment was defined for patients in each group according to their priorities.

Study Design

Study Type:
Observational
Actual Enrollment :
50 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
The Impact of the COVID-19 Pandemic on Oncologic Outcomes of Testicular Cancer
Actual Study Start Date :
Jul 1, 2021
Actual Primary Completion Date :
Mar 15, 2022
Actual Study Completion Date :
Mar 25, 2022

Arms and Interventions

Arm Intervention/Treatment
COVID-19 Testicular Cancer

Patients diagnosed with testicular cancer in the COVID-19 period

Behavioral: COVID-19 pandemic
Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.

PreCOVID-19 Testicular Cancer

Patients diagnosed with testicular cancer before the COVID-19 period

Behavioral: COVID-19 pandemic
Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.

Outcome Measures

Primary Outcome Measures

  1. Rate of tumor stages [2 month]

    Rate of tumor stages in patients who diagnosed with testicular cancer

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients diagnosed with testicular cancer in the urology clinic.
Exclusion Criteria:
  • Previous history of genitourinary system tumor

  • Previous history of radiotherapy or chemotherapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ankara Training and Research Hospital Ankara Altindag Turkey 06230

Sponsors and Collaborators

  • Ankara Training and Research Hospital

Investigators

  • Principal Investigator: Ali Kaan Yıldız, Ankara Training and Resarch Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ali Kaan Yildiz, Principal Investigator, Ankara Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT05083143
Other Study ID Numbers:
  • COVIDTC2021
First Posted:
Oct 19, 2021
Last Update Posted:
Apr 27, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ali Kaan Yildiz, Principal Investigator, Ankara Training and Research Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 27, 2022